Therapeutic update in large vessel vasculitides;Actualizacion terapeutica en las vasculitis de grandes vasos

Revista Clinica Espanola

Volumn 213, Issue 7, 2013, Pages 338-346

  Perez Esteban S ^a   Gonzalez Gay M A ^b   Castaneda S ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Anti TNF agents; Giant cell arteritis; Large vessel vasculitis; Takayasu's arteritis; Tocilizumab

Indexed keywords

GLUCOCORTICOID;

AORTA ARCH SYNDROME; ARTICLE; CAROTID ARTERY; CLINICAL FEATURE; DRUG MEGADOSE; GIANT CELL ARTERITIS; HUMAN; INCIDENCE; SOUTHERN EUROPE; ADOLESCENT; ALGORITHM; CASE REPORT; FEMALE; TAKAYASU ARTERITIS;

ADOLESCENT; ALGORITHMS; FEMALE; GIANT CELL ARTERITIS; HUMANS; TAKAYASU ARTERITIS;

EID: 84885941847     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2013.03.008     Document Type: Article

References (49)

1. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33:1135-6. (Pubitemid 20273299)
2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
3. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43:294-301. (Pubitemid 38313176)
4. Rueda B, López-Nevot MA, López-Díaz MJ, García-Porrua C, Martín J, González-Gay MA. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol. 2005;32:1737-41. (Pubitemid 41324813)
5. Mason JC. Takayasu arteritis: advances in diagnosis and management. Nat Rev Rheumatol. 2010;6:406-15.
6. Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum. 2005;53:100-7. (Pubitemid 40216358)
7. Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009;48:1008-11.
8. González Gay MA, Rueda J, Pina T. Arteritis de células gigantes y enfermedad de Takayasu. En: María C Cid, Rosa Solans, editores. Avances en Enfermedades Autoinmunes Sistémicas. Barcelona: Marge Medica Books; 2012. p. 19-38.
9. González-Gay MA, Vázquez-Rodríguez TR, López-Díaz MJ, Miranda-Filloy JA, González-Juanatey C, Martín J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454-61.
10. González-Gay MA, Barros S, López-Díaz MJ, García-Porrua C, Sánchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84:269-76. (Pubitemid 41368480)
11. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47:96-101. (Pubitemid 350286272)
12. Carmona FD, Rodríguez-Rodríguez L, Castañeda S, Miranda-Filloy JA, Morado IC, Narváez J, et al. Role of the CCR5/(32CCR5 polymorphism in biopsy-proven giant cell arteritis. Hum Immunol. 2011;72:458-61.
13. Yoshida S, Akiba H, Tamakawa M, Yama N, Takeda M, Hareyama M, et al. The spectrum of findings in supra-aortic Takayasu's arteritis as seen on spiral CT angiography and digital subtraction angiography. Cardiovasc Intervent Radiol. 2001;24:117-21. (Pubitemid 32410916)
14. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33:1129-34. (Pubitemid 20273298)
15. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population based study. Arthritis Rheum. 2001;45:140-5. (Pubitemid 32954439)
16. López-Díaz MJ, Llorca J, González-Juanatey C, Peña-Sagredo JL, Martín J, González-Gay MA. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008;38:116-23.
17. González-Gay MA, García-Porrua C, Llorca J, González-Louzao C, Rodríguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum. 2001;30:249-56. (Pubitemid 32172730)
18. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis. Ann Intern Med. 1994;120:987-92. (Pubitemid 24169277)
19. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337:1336-42. (Pubitemid 27467767)
20. González-Gay MA, Martínez-Dubois C, Agudo M, Pompei O, Blanco R, Llorca J. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12: 436-42.
21. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-8. (Pubitemid 20273297)
22. Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1481-91.
23. González-Gay MA, García-Porrúa C, Llorca J, Hajeer AH, Brañas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283-92.
24. Martínez-Lado L, Calviño-Díaz C, Piñeiro A, Dierssen T, Vázquez-Rodríguez TR, Miranda-Filloy JA, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90:186-93.
25. Borg FA, Dasgupta B. Treatment and outcomes of large vessel arteritis. Best Pract Res Clin Rheumatol. 2009;23:325-37.
26. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919-29. (Pubitemid 24179154)
27. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703-8. (Pubitemid 37296477)
28. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515-26.
29. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37:578-82. (Pubitemid 24115946)
30. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106-14. (Pubitemid 32096337)
31. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309-18. (Pubitemid 34525840)
32. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789-97. (Pubitemid 47237299)
33. Henes JC, Mueller M, Pfannenberg C, Kanz L, Koetter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol. 2011;29 Suppl 64: S43-8.
34. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/ polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45:136-8. (Pubitemid 16162481)
35. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Antitumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296-304. (Pubitemid 38924409)
36. Mekinian A, Néel A, Sibilia J, Cohen P, Connault J, Lambert M, et al. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012;51:882-6.
37. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term follow-up. Arthritis Care Res (Hoboken). 2012;64: 1079-83.
38. Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, et al. Anti TNF-in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev. 2012;11:678-84.
39. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621-30. (Pubitemid 351650517)
40. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625-30. (Pubitemid 351571925)
41. Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ, et al. Elevated production of interleukin-6 is associated with a lower incidence of diseaserelated ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation. 2003;107: 2428-34. (Pubitemid 36605224)
42. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456-8.
43. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51: 151-6.
44. Schafer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol. 2012;24:31-7.
45. Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis. 2012;71: 75-9.
46. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64:1099-100. (Pubitemid 40909539)
47. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis. Rheumatology (Oxford). 2006;45:600-5.
48. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischaemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332-7. (Pubitemid 38480844)
49. González-Gay MA, Piñeiro A, Gómez-Gigirey A, García-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83:342-7. (Pubitemid 39541111)